Owner Aventis Pharma S.A.

Inventors Angouillant-Boniface, Odile; Viviani, Fabrice; Desmazeau, Pascal; Souaille, Catherine; Gauzy-Lazo, Laurence; Le Brun, Alain; Tabart, Michel; Halley, Franck; Filoche-Romme, Bruno; Bouchard, Herve

Agent Davies Collison Cave

Pub. Number AU-B-2005259139

PCT Pub. Number WO2006/003276

Priority 0406042 04.06.04 FR

Filing date 1 June 2005

Wipo publication date 12 January 2006

Acceptance publication date 8 September 2011

C07D 409/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

A61K 31/416 (2006.01) - condensed with carbocyclic ring systems, e.g. indazole

A61P 35/00 (2006.01) Antineoplastic agents

C07D 231/56 (2006.01) Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

C07D 409/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms

C07D 413/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms